Vornorexant

 ( Experimental Psychiatric Drugs ) 

Vornorexant, also known by its developmental code names ORN-0829 and TS-142, is an orexin antagonist medication which is under development for the treatment of insomnia and sleep apnea. It is a dual orexin receptor OX₁ and OX₂ receptor antagonist (DORA). The medication is taken by mouth. As of June 2021, vornorexant is in phase 2 for insomnia and phase 1 trials for sleep apnea. It is under development by Taisho Pharmaceutical.

Vornorexant has a time to peak of 2.5hours and a relatively short elimination half-life of 1.3 to 3.3hours. It was designed to have a short half-life and duration in order to reduce next-day like somnolence.

• Seltorexant – another investigational short-acting orexin receptor antagonist
• List of investigational insomnia drugs

• Vornorexant (ORN-0829, TS-142) - AdisInsight